Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas
Trial status: Open for Enrollment
Why is this study being done?
The purpose of this study is to use a nutrient called 18F-FDOPA and PET/CT scan to help determine where and how big the tumor is, as well as how aggressive the tumor is. This will help treating physicians to target diseased areas with higher than standard doses of radiation, in order to improve the effectiveness of radiation in this tumor.
Who is eligible to participate?
- Age ≥18 years.
- Histologically confirmed newly diagnosed high-grade malignant glioma.
- Planned radiation treatments at Mayo Clinic Rochester.
- Willing to sign release of information for any radiation and/or follow-up records.
- Provide informed written consent.
- Patients with eGFR ≥ 60 mg/min/1.72m2
- Ability to complete questionnaire(s) by themselves or with assistance.
- Patients diagnosed with anaplastic oligodendroglioma
- Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure).
- Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists)
- Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception